A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
A COLCHESTER pharmacy boss is “delighted” to offer a weight loss drug which has been used by celebrities through a new ...
A new study reveals a novel connection between aging of visceral adipose tissue and brain health. These findings are ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...
Higher adherence to the Mediterranean diet reduced the risk of obesity-related cancers, but not in the way researchers ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
Jonathan Van Ness is sharing details about their recent weight loss. “All right, I have a confession to make,” the “Queer Eye” star said in a recent TikTok video. “Yes, I am on a GLP-1, or a weight ...
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...